Table 3.

Patient schedule of events

Patient registration	Screening	Visit 1 Transplant Day 0	Visit 2 Day 30 (+/−3 days)	Visit 3 Day 90 (+3 days)	Visit 4 Day 180 (+30 days)	Extended follow-up 12 months+24 months (+/− 30 days)
Informed consent	X
Eligibility assessment	X	X
Patient history	X	X
Standard routine blood tests*	X	X	X	X	X	X
MELD (automatically calculated)		X
UKELD (automatically calculated)		X
Trial-specific additional patient samples blood and urine		X	X	X	X
PBMC collection		X	X	X	X
Liver biopsy 4 (see table 2)		X
Quality of life questionnaire (EQ-5D-5L)		X	X		X
Patient resource log at visit one discharge		X
Adverse/Clinical events	X	X	X	X	X	X
Concomitant medications	X	X	X	X	X	X
MRCP					X

*Standard routine blood tests—FBC, urea, electrolytes, liver function tests, AST, GGT, eGFR, INR.

AST, aspartate transaminase; eGFR, estimated glomerular filtration rate; EQ-5D-5L, EuroQoL 5 Dimensions 5 Levels; FBC, full blood count; GGT, gamma glutamyl transferase; INR, international normalised ratio; MELD, model for end-stage liver disease; MRCP, magnetic resonance cholangiopancreatography; PBMC, peripheral blood mononuclear cell; UKELD, UK end-stage liver disease.